Abstract
Patient-derived xenografts (PDX) are a relevant approach to the study of glioblastomas (GBM) since these cells mimic tumor characteristics in vitro. GBM is the most aggressive and difficult-to-treat primary brain tumor, and its high malignancy and resistance to therapy are due, among other factors, to a subpopulation of tumor stem cells known as glioblastoma stem-like cells (GSCs). Althou…